Genetic modifiers of ambulation in the cooperative international Neuromuscular research group Duchenne natural history study

Eccentric muscle challenge shows osteopontin polymorphism modulation of muscle damage

(2014) W. L. Barfield et al.   HUMAN MOLECULAR GENETICS

Trends With Corticosteroid Use in Males With Duchenne Muscular Dystrophy Born 1982-2001

(2014) Deborah J. Fox et al.   JOURNAL OF CHILD NEUROLOGY

Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessingSPP1andLTBP4variants

(2014) Janneke C van den Bergen et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Milder course in Duchenne patients with nonsense mutations and no muscle dystrophin

(2014) M. Zatz et al.   NEUROMUSCULAR DISORDERS

VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects

(2013) Christopher R. Heier et al.   EMBO Molecular Medicine

Modifying muscular dystrophy through transforming growth factor-β

(2013) Ermelinda Ceco et al.   FEBS Journal

Alterations in Osteopontin Modify Muscle Size in Females in Both Humans and Mice

(2013) ERIC P. HOFFMAN et al.   MEDICINE AND SCIENCE IN SPORTS AND EXERCISE

The cooperative international neuromuscular research group duchenne natural history study-a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used

(2013) Craig M. McDonald et al.   MUSCLE & NERVE

The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and othe

(2013) Erik K. Henricson et al.   MUSCLE & NERVE

LTBP4genotype predicts age of ambulatory loss in duchenne muscular dystrophy

(2012) Kevin M. Flanigan et al.   ANNALS OF NEUROLOGY

Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy

(2012) V. Ricotti et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

TGFBR2 but not SPP1 genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle

(2012) Luisa Piva et al.   JOURNAL OF PATHOLOGY

Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy

(2012) L. Bello et al.   NEUROLOGY

Disparities in the diagnostic process of Duchenne and Becker muscular dystrophy

(2011) Caleb Holtzer et al.   GENETICS IN MEDICINE

Predicting the severity of Duchenne muscular dystrophy: Implications for treatment

(2010) S. F. Nelson et al.   NEUROLOGY

SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy

(2010) E. Pegoraro et al.   NEUROLOGY

Latent TGF-β–binding protein 4 modifies muscular dystrophy in mice

(2009) Ahlke Heydemann et al.   JOURNAL OF CLINICAL INVESTIGATION

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management

(2009) Katharine Bushby et al.   LANCET NEUROLOGY

Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care

(2009) Katharine Bushby et al.   LANCET NEUROLOGY

The positives, protocols, and perils of genome-wide association

(2008) Benjamin M. Neale et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

Identifying modifier genes of monogenic disease: strategies and difficulties

(2008) Emmanuelle Génin et al.   HUMAN GENETICS

Accounting for ancestry: population substructure and genome-wide association studies

(2008) C. Tian et al.   HUMAN MOLECULAR GENETICS